Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Ultragenyx To Contact Him Directly To Discuss Their Options If you purchased or acquired securities in Ultragenyx between August 3, 2023 and December 26, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). [You may also click here for additional information] NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- ...

Market Overview - The S&P 500 and Nasdaq experienced declines for the third consecutive session, with the S&P 500 down 1% and the Nasdaq down 1.4%, putting both indices in negative territory year-to-date [1][1] - Bitcoin and silver prices fell significantly, while investors shifted towards bonds for safety [1] Company Performances - Bristol Myers Squibb reported strong earnings, leading to a nearly 3.5% increase in its stock [1] - Procter & Gamble also saw a gain of 1% during the session [1] - Salesforce's stock dropped 4.5% amid concerns that AI tools could replace enterprise software solutions [1] - Alphabet shares were down more than 1.5% but recovered from earlier lows after reporting strong cloud growth and AI investments [1] Boeing and Airbus Developments - Boeing shares rose nearly 2% following reports of talks with Saudi Arabia's flagship carrier for a potential record-breaking order of at least 150 jets [1] - Citi analysts have a bullish outlook on Boeing, citing improved deliveries and reiterating a buy rating [1] - Jefferies forecasted potential new orders from China for Boeing, linked to trade negotiations [1] Costco Sales Growth - Costco's stock advanced more than 1%, contributing to a 15% gain year-to-date after reporting a 6.4% increase in core comparable sales for January, surpassing the consensus of 5.1% [1] - The growth was driven by strong sales in non-food items and favorable weather conditions [1] Upcoming Earnings Reports - Amazon is set to release earnings, with expectations on how it will leverage AI to enhance its business [1] - Fortinet's earnings release could impact related cybersecurity stocks like Palo Alto Networks and CrowdStrike, which have been affected by the enterprise software downturn [1]

Novo Nordisk’s patents on semaglutide, the active ingredient in Ozempic, are starting to expire. On today’s Big Take podcast, @davidgura talks to @naomikresge and @AmberTongPW about how the company is navigating a dire 2026 sales projection as generic versions are poised to upend.🎙️ Listen now: https://t.co/yT3DsoVeH6 ...

Core Viewpoint - Johnson & Johnson (NYSE: JNJ) is recognized as one of the best dividend stocks with a wide economic moat, indicating strong competitive advantages in the market [1]. Financial Performance - For the full year 2025, Johnson & Johnson reported a revenue increase of 6% to $94.2 billion, consistent with historical performance [3]. - The company anticipates a revenue growth of approximately 6.7% for 2026, projecting revenues of $100.5 billion, indicating positive momentum [4]. Strategic Focus - Johnson & Johnson aims to become the leading cancer drugmaker, targeting $50 billion in oncology revenue, which would be double the revenue generated by this segment in the previous year [3]. - The management has expressed a more confident outlook, suggesting a clearer path to double-digit growth by the end of the decade [3]. Analyst Insights - RBC Capital has raised its price target for Johnson & Johnson to $255 from $240, maintaining an Outperform rating, while acknowledging ongoing legal challenges stemming from the Daubert ruling [2]. - The firm believes that Johnson & Johnson's strong balance sheet and improving operational trends provide the company with the capacity to manage associated risks [2].

Core Viewpoint - Merck & Co., Inc. (NYSE:MRK) has received a price target increase from Scotiabank, reflecting strong execution despite a cautious outlook for 2026 due to potential revenue pressures from product exclusivity losses [2][3]. Group 1: Financial Performance - Merck reported a strong fourth quarter, exceeding revenue and earnings expectations, primarily driven by demand for its cancer immunotherapy Keytruda [4]. - The company anticipates 2026 revenue to be between $65.5 billion and $67.0 billion, which is below the consensus estimate of $67.6 billion [4]. - Merck expects approximately $2.5 billion in revenue pressure this year due to factors such as increased generic competition, Medicare price negotiations, and declining sales of its COVID-19 treatment, Lagevrio [4]. Group 2: Product Outlook - Management indicated that several drugs, including Januvia and related therapies, may underperform expectations, impacting near-term results [5]. - The company is focusing on longer-term growth drivers across its broader portfolio, despite short-term challenges [5]. Group 3: Company Overview - Merck & Co., Inc. is a global healthcare company that specializes in prescription medicines, including biologic therapies, vaccines, and animal health products, with a strong emphasis on human health drugs and vaccines [6].

Novo Nordisk and Eli Lilly are facing an uncomfortable new price point this week after a $49 weight-loss pill jolted the GLP-1 market. By launching a low-cost, compounded oral version of semaglutide, ... ...

Core Insights - Amgen Inc. (NASDAQ:AMGN) is recognized as one of the 15 Best Wide Moat Dividend Stocks to invest in [1] - RBC Capital raised its price target for Amgen to $360 from $335, maintaining an Outperform rating, citing strong fourth-quarter performance driven by key drugs [2] - Amgen's fourth-quarter results exceeded Wall Street expectations, with shares experiencing a modest increase due to confidence in its weight-loss drug MariTide [3] Financial Performance - Quarterly revenue increased by 9% year-over-year to $9.9 billion, surpassing the consensus estimate of $9.5 billion [4] - Adjusted earnings per share were reported at $5.29, significantly above expectations of $4.73, despite ongoing pricing pressures [4] - Product sales volumes rose by 10%, while net prices declined by 4%, resulting in a 7% quarter-over-quarter growth [5] Future Outlook - Amgen anticipates adjusted earnings per share between $21.60 and $23.00 for 2026, with Wall Street estimating $22.09 [5] - The company forecasts full-year revenue of $37 billion to $38.4 billion, compared to analysts' expectations of $37.1 billion [5] - Amgen is actively conducting six Phase 3 trials for its weight-loss drug MariTide and plans to initiate additional studies in diabetes patients later this year [4] Company Strategy - Amgen focuses on developing, manufacturing, and delivering medicines for challenging diseases, with a strategy centered on high unmet medical needs [6] - The company's pipeline is designed to support growth beyond its established products, indicating a long-term commitment to innovation in the healthcare space [4][6]

Telehealth company Hims & Hers is launching a cheaper, off-brand version of the blockbuster weight loss pill WegovyFILE - This photo shows Novo Nordisk headquarters in Bagsvaerd, Denmark, on Feb. 5, 2025. (Mads Claus Rasmussen/Ritzau Scanpix via AP, File)WASHINGTON -- Telehealth company Hims & Hers said Thursday it will launch a cheaper, off-brand version of the weight-loss pill Wegovy, just weeks after drugmaker Novo Nordisk launched its highly anticipated reformulation of the blockbuster medication.The an ...

Core Viewpoint - Eli Lilly's stock is experiencing a decline due to profit-taking after a significant rally, despite strong earnings and sales performance in the fourth quarter [1][6]. Financial Performance - Eli Lilly reported fourth-quarter adjusted earnings of $7.54 per share, surpassing the consensus estimate of $6.67 [1]. - The company's sales reached $19.3 billion, exceeding the consensus of $17.96 billion [1]. - For fiscal 2026, Eli Lilly expects adjusted earnings between $33.50 and $35 per share, compared to the consensus of $33.23 [2]. Sales Projections - Eli Lilly anticipates total sales between $80 billion and $83 billion for fiscal 2026, higher than Wall Street's estimate of $77.62 billion [1]. - The topline estimate of around $82 billion for fiscal 2026 suggests incretin sales of approximately $57 billion, an increase of about $16 billion over fiscal 2025 [4]. Analyst Insights - Cantor's analyst views Eli Lilly's fiscal 2026 guidance as a strong rebuttal to concerns regarding GLP-1 pricing or demand, maintaining an Overweight rating with a price forecast increase to $1,205 from $985 [3]. - The expectation is for over 3 million orforglipron prescriptions in fiscal 2026, which is considered reasonable given various market factors [5].

Core Insights - The Trump administration is launching TrumpRx, a government-run website aimed at helping patients obtain prescription drugs directly from manufacturers at lower prices, addressing rising healthcare costs for Americans [2][3][4] Group 1: TrumpRx Overview - TrumpRx is designed to facilitate access to lower-cost prescription drugs by directing consumers to drugmakers' direct-to-consumer sites rather than selling medications directly [2] - The initiative is part of a broader effort by the Trump administration to reduce prescription drug costs, with agreements from major pharmaceutical companies like Johnson & Johnson to provide medications at prices comparable to those in other developed nations [3][6] Group 2: Agreements with Pharmaceutical Companies - The Trump administration has secured agreements with several major pharmaceutical companies, including Pfizer, Eli Lilly, and Merck, to lower prices on certain Medicaid drugs to "most favored nations" levels [6] - Johnson & Johnson's agreement includes participation in TrumpRx, which aims to offer significant discounts to consumers [3][4] Group 3: Launch Details and Delays - The launch of TrumpRx was announced to take place on Thursday evening, following several delays that have not been publicly explained [5] - The president had previously hinted at the initiative in September, with expectations of "massive discounts" for consumers, although it remains uncertain if the prices will consistently undercut current insurance costs [4][5]